NuVision Biotherapies

NuVision Biotherapies is a private, commercial-stage biotech focused on regenerative medicine for ophthalmology. Leveraging its patented Tereo® preservation technology, the company has launched two key products: Omnigen, a ready-to-use amniotic membrane graft for wound healing, and OmniLenz, a custom contact lens for rapid, non-surgical care. Founded on 15 years of translational research from the University of Nottingham, NuVision is led by an experienced team with deep medical device industry expertise and is building a portfolio to address significant unmet needs in ocular surface disease.

Patented Tereo® process for the ambient-temperature preservation of human amniotic membrane, retaining its natural barrier function and biological activity for use as a wound dressing and grafting material.

NuVision competes in the amniotic membrane and ocular wound care market against companies offering cryopreserved amniotic membrane (e.g., TissueTech's AmnioGraft, Katena's AmbioDisk) and synthetic corneal bandages. Its primary competitive edge is the room-temperature stability of Omnigen, which offers convenience and potential cost savings. It also faces indirect competition from pharmaceutical treatments for dry eye disease and other advanced cell-based therapies in development.